🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Malignant Tumour

MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors NCT06912152Phase 11 site📍 Hangzhou Zhejiang University · Tests: MT027 CAR-T cells A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) NCT07785609Phase 24 sites📍 San Antonio📍 Hong Kong📍 Bellinzona Merck Sharp & Dohme LLC · Tests: MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or… A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers NCT06606990Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors NCT07387068Phase 112 sites📍 New Haven📍 Grand Rapids📍 Lake Success Genmab · Tests: GEN1079 Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors NCT07644650Phase 11 site📍 Shanghai Mabsoft Therapeutics (Shanghai) Co., Ltd. · Tests: MST-168 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors NCT05615974Phase 1, Phase 25 sites📍 Guangzhou📍 Wuhan📍 Linyi LaNova Medicines Limited · Tests: LM101, Toripalimab, Rituximab Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413Phase 12 sites📍 Fairway📍 Bethesda National Cancer Institute (NCI) · Tests: Metarrestin JSKN022 in Subjects With Advanced Malignant Solid Tumors NCT07292402Phase 11 site📍 Guangzhou Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN022 CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Study of MHB088C for Patients With Advanced Solid Malignant Tumors NCT07102004Phase 1, Phase 21 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: MHB088C for Injection Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma NCT07126509NA1 site📍 Chicago University of Chicago · Tests: Partial Pleurectomy Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial NCT06470971Phase 21 site📍 Columbus Yuanquan Yang · Tests: Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors NCT04879121Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Larotrectinib Sulfate Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors NCT05141474EARLY Phase 11 site📍 Barcelona Vall d'Hebron Institute of Oncology · Tests: NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen, Interleukin-2 Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors NCT07583654Phase 11 site📍 Chengdu West China Hospital · Tests: CP-IL22BP mRNA intratumorally injection Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors NCT05749627NA1 site📍 Nanchang The First Affiliated Hospital of Nanchang University · Tests: Neoantigen peptide vaccine, Neoantigen-based DC immune preparation A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors NCT06658951NA1 site📍 Zhengzhou UTC Therapeutics Inc. · Tests: Anti-HER2 CAR-T cells Atamparib in Patients With Advanced Solid Tumors NCT07374419Phase 1, Phase 21 site📍 Shanghai Nerviano Medical Sciences (Shanghai) Ltd. · Tests: atamparib escalation levels, atamparib RP2D AZD5305 hADME in Patients With Advanced Solid Malignancies NCT06713369Phase 12 sites📍 Liverpool📍 Manchester AstraZeneca · Tests: Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose) Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma NCT07885319Phase 1, Phase 23 sites📍 Shanghai📍 Shanghai📍 Chengdu Ruijin Hospital · Tests: Ivonescimab Combined With Chemotherapy MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154Phase 21 site📍 Guangzhou HRYZ Biotech Co. · Tests: MASCT-I, Doxorubicin, Ifosfamide A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) NCT05865002Phase 137 sites📍 Vijayawada📍 Visakhapatnam📍 Chandigarh Aurigene Discovery Technologies Limited · Tests: AUR107 A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors NCT06390774Phase 11 site📍 Jinan Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: SSGJ-705 Study of LM-299 in Subjects Advanced Malignant Tumors NCT06650566Phase 1, Phase 26 sites📍 Perth📍 Xinxiang📍 Liaocheng LaNova Medicines Limited · Tests: LM-299 Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT) NCT07026422Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma NCT07469683Phase 21 site📍 Seoul Yonsei University · Tests: SLC-3010 + Axitinib, Axitinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy